V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

Viruses from 15 of 35 maraviroc-treated participants with virologic failure and CCR5-tropic (R5) virus in the MOTIVATE studies at Week 24 had reduced maraviroc susceptibility. On-treatment amino acid changes were observed in the viral envelope glycoprotein 120 third variable (V3)–loop stems and tips...

Full description

Bibliographic Details
Main Authors: ME Lewis, P Simpson, J Mori, B Jubb, J Sullivan, L McFadyen, E van der Ryst, C Craig, DL Robertson, M Westby
Format: Article
Language:English
Published: SAGE Publishing 2021-07-01
Series:Antiviral Chemistry & Chemotherapy
Online Access:https://doi.org/10.1177/20402066211030380

Similar Items

Similar Items